Premium
Pulmonary Zygomycosis in Solid Organ Transplant Recipients in the Current Era
Author(s) -
Sun H.Y.,
Aguado J. M.,
Bonatti H.,
Forrest G.,
Gupta K. L.,
Safdar N.,
John G. T.,
Pursell K. J.,
Muñoz P.,
Patel R.,
Fortun J.,
MartinDavila P.,
Philippe B.,
Philit F.,
Tabah A.,
Terzi N.,
Chatelet V.,
Kusne S.,
Clark N.,
Blumberg E.,
Julia M. B.,
Humar A.,
Houston S.,
LassFlorl C.,
Johnson L.,
Dubberke E. R.,
Barron M. A.,
Lortholary O.,
Singh N.
Publication year - 2009
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2009.02754.x
Subject(s) - medicine , zygomycosis , solid organ , intensive care medicine , organ transplantation , transplantation , dermatology , amphotericin b , antifungal
Fifty‐eight solid organ transplant recipients with zygomycosis were studied to assess the presentation, radiographic characteristics, risks for extra‐pulmonary dissemination and mortality of pulmonary zygomycosis. Pulmonary zygomycosis was documented in 31 patients (53%) and developed a median of 5.5 months (interquartile range, 2–11 months) posttransplantation. In all, 74.2% (23/31) of the patients had zygomycosis limited to the lungs and 25.8% (8/31) had lung disease as part of disseminated zygomycosis; cutaneous/soft tissue (50%, 4/8) was the most common site of dissemination. Pulmonary disease presented most frequently as consolidation/mass lesions (29.0%), nodules (25.8%) and cavities (22.6%). Patients with disseminated disease were more likely to have Mycocladus corymbifer as the causative pathogen. The mortality rate at 90 days after the treatment was 45.2%. In summary, pulmonary zygomycosis is the most common manifestation in solid organ transplant recipients with zygomycosis, and disseminated disease often involves the cutaneous/soft tissue sites but not the brain.